SCHEMBL5830640

SCHEMBL5830640

O=C1COCCN1CCc1nsc(NS(=O)(=O)c2ccc(Cl)cc2Cl)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.39
SCN9A Q15858 2/20 0.36
EDNRA P25101 2/20 0.35
MAPT P10636 4/20 0.35
RECQL P46063 2/20 0.35
POLB P06746 2/20 0.35
USP2 O75604 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SGK1 O00141 1/20 0.34
EDNRB P24530 1/20 0.34
SLC40A1 Q9NP59 1/20 0.34
LMNA P02545 3/20 0.34
MAPK1 P28482 1/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6623535 0.89 HSD11B1 (0.38) HSD11B1EDNRANMT1
SCHEMBL5831882 0.88 HSD11B1 (0.46) HSD11B1SCN9ASLC40A1LMNAMAPK1
SCHEMBL5831634 0.86 KMT2A (0.43) HSD11B1MAPTLMNAMAPK1KMT2A
SCHEMBL5831063 0.85 HSD11B1 (0.44) HSD11B1SCN9AEDNRAEDNRBSLC40A1
SCHEMBL3615630 0.85 HSD11B1 (0.47) HSD11B1EDNRAMAPTRECQLPOLB
SCHEMBL27603916 0.84 SCN9A (0.34) HSD11B1SCN9ALMNAEPHX2
SCHEMBL5831444 0.84 HSD11B1 (0.41) HSD11B1SCN9AMAPTLMNAMAPK1
SCHEMBL5830780 0.84 SCN9A (0.34) HSD11B1SCN9ALMNAMEN1KMT2A
SCHEMBL3255250 0.84 HSD11B1 (0.40) HSD11B1EDNRAMAPTUSP2SGK1
SCHEMBL5830894 0.84 KMT2A (0.41) HSD11B1EDNRAMAPTPOLBEDNRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US claimed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 HSD11B1 2/4885SCN9A 2228/4885EDNRA 1367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.